You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. DGPS-Based Trilateration Positioning Receiver

    SBC: Swaszek Peter            Topic: 07FH1

    Positioning and navigation have become a mainstay of everyday life in the U.S.; applications of interest include navigation of vehicles of all kinds, infrastructure mapping, and safety of life systems. Many of these recent applications have become possible through the GPS. With the recognized vulnerabilities of GPS, it is evident that equivalent backup systems must be developed. One possible so ...

    SBIR Phase I 2008 Department of Transportation
  2. Engineered Spores as Fluorogenic Biological Indicators for Sterility Testing

    SBC: BCR DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): BCR Diagnostics, Inc. (BCR) has recently developed and patented a technology platform for engineering fluorogenic functionality into living Bacillus spores. Fluorogenic spores (F-spores) produced at BCR appear to be phy siologically identical to normal spores except for performing as self reporters of initial germination events. Considering the unique features ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  3. T1D Tolerance Induction with Natural Treg Epitopes

    SBC: EPIVAX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Type 1 (juvenile) diabetes is an organ-specific autoimmune disease resulting from destruction of insulinproducing pancreatic beta-cells. In non-diabetics, islet cell antigen-specific T cells are either deleted in thymic development or are converted to T regulatory cells that actively suppress effector responses to islet cell antigens. In juvenile diabetics and ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Ultra-low-power analog seizure detection algorithm

    SBC: FLINT HILLS SCIENTIFIC, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Development of implantable devices for automated detection, quantification, warning and delivery of therapy to block seizures is a very important unmet medical need. Making such a device as small as possible, minimizin g replacement surgeries, and maximizing device longevity and/or time between battery recharging are some of the most important development driv ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. IN-PLACE AIR PERMEAMETER FOR OPEN-GRADED DRAINAGE LAYERS

    SBC: Geo-systems Engineering Inc.            Topic: N/A

    A RAPID FIELD TEST IS PROPOSED TO EVALUATE THE PERMEABILITY OF OPEN-GRADED ROAD BASES AND OTHER DRAINAGE LAYERS. THE SAME TEST ALSO SHOULD BE ADAPTABLE TO EVALUATE PERMEABILITIES OF OTHER EXPOSED PAVEMENT LAYERS INCLUDING THOSE COMPOSED OF BITUMINOUS OR PORTLAND CEMENT CONCRETES, AS AN INDEX TO PERMEATION AND POSSIBLY TO DETERIORATION. IT IS PROPOSED THAT THE PERMEABILITY BE EVALUATED THROUGH USE ...

    SBIR Phase I 1989 Department of Transportation
  6. ADVANCED DE-ICING FLUIDS FOR GENERAL AVIATION AIRCRAFT

    SBC: Kohlman Aviation Corp            Topic: N/A

    THE PROPOSED PROJECT WILL DETERMINE THE FEASIBILITY OF THE USE OF ADVANCED TYPE II FLUIDS FOR THE DE-ICING/ANTI-ICING OF GENERAL AVIATION (GA) AIRCRAFT WITH TAKEOFF SAFETY SPEEDS (V2) OF GENERALLY LESS THAN 85 KNOTS. TYPE II FLUIDS WILL BE APPLIED TO SEVERAL GA CATEGORY AIRCRAFT. THE ICE PROTECTION CAPABILITY OF THE FLUID WILL BE EVALUATED FOR DIFFERENT FREEZING PRECIPITATION CONDITIONS. THE EFFEC ...

    SBIR Phase I 1989 Department of Transportation
  7. High Content Drug Screening with Cardiac Tissue

    SBC: MYOMICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Myomics, Inc. has developed High Content Drug Screening (HCS) technology for in vitro testing of compounds which alter contractile forces generated by miniaturized tissue engineered organs (Myo-Force Assay SystemTM, MFA STM). Myomics' 3-D tissue/force sensor composite is capable of long term studies (1-4 weeks) and provides force as well as electrophysiological ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. SBIR TOPIC 252- FUNCTIONALIZED BIMAGNETIC CORE/SHELL FE/FE3O4 STEALTH NANOPARTIC

    SBC: NanoScale Materials, Inc.            Topic: N/A

    Early diagnosis and early treatment of cancer greatly improve the likelihood of long-term survival and health. Chemical structures that are selectively taken by cancerous tissue can be used to pull diagnostic and therapeutic moieties to cancerous tissue. Appropriately sized iron and/or iron oxide nanoparticles are effective for both diagnosis (via magnetic resonance imaging, MRI) and therapy (by h ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. OCEAN WAVE ENERGY CONVERTER

    SBC: Ocean Wave Energy Co            Topic: N/A

    MAJOR AIDS TO NAVIGATION (ATON) ARE ESSENTIAL SIGNPOSTS FOR SAFE PASSAGE ALONG COASTAL AND OFFSHORE SEAWAYS. PRESENTLY, THEIR SIGNALS ARE POWERED BY ON-SITE ENGINE GENERATORS REQUIRING CONSIDERABLE AND COSTLY MAINTENANCE. ATON AUTONOMY WILL BE GREATLY INCREASED WITH DEEP DISCHARGE BATTERY TECHNOLOGY PROVIDING THAT ON-SITE CHARGING SOURCES ARE USED. AMONG NATURALLY AVAILABLE SOURCES, THE UNCEASING ...

    SBIR Phase I 1989 Department of Transportation
  10. Anabolic Therapeutics for Increasing Bone Denisty and Quality

    SBC: OsteoGeneX Inc            Topic: N/A

    DESCRIPTION (provided by applicant): OsteoGeneX is developing a therapeutic directed against the new bone target Sclerostin (SOST) for the treatment of osteoporosis and related bone disorders. Through genomic approaches Sclerostin was identified as a mast er regulator of bone mass affecting men and women. Using proteomic approaches Dr. Ellies and Krumlauf discovered and patented Sclerostin's mech ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government